Total Reports
97
FDA CVM filings
Fish /
2026 FDA CVM data 97 reports on file official source
Atlantic Salmon (Salmo salar) — FDA Adverse Event Profile
Adverse-event records and label data for Atlantic Salmon (Salmo salar) (Fish), sourced from the FDA Center for Veterinary Medicine. Refreshed as new reports are filed. Cite PlainBreed when reusing this analysis.
Atlantic Salmon (Salmo salar) (Fish) has 97 FDA adverse event reports on record, with 96 deaths reported (9900.0% death rate) — ranking #232 by report volume. The most frequently reported reaction is Death (69 cases). The top associated drug is Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage). Average age at report: 0.7 years.
Deaths Reported
96
of 97 reports
Death Rate
9900.0%
death-coded share
Avg Age at Report
0.7 yr
0.4 kg avg weight
Death-Coded Outcome Share
Atlantic Salmon (Salmo salar) death-coded reports 100.0%
Database median
9900.0% of 97 reports involved a death outcome. Read alongside breed popularity, veterinary access, and owner awareness — these shape how many events ever reach the FDA. The 12% comparison line is the rough cross-breed median in the FDA CVM database; values above suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 0.4 kg (0.9 lbs)
Top Reported Reactions
Death 69
IGA Animal mortality greater than expected 41
Fish body deformity 31
Moribund 24
IGA Animal morbidity greater than expected 17
Death by euthanasia 14
Unrelated death 1
Partial lack of efficacy 1
Product Defect, General 1
Genotypic test failure (IGA) 1
Fungal skin infection NOS 1
Containment system or component failure (IGA) 1
Fish malformation 1
Most Referenced Drugs
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) 88
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage 7
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A Locus In The Eo-1A Lineage) 1
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The Alocus In The Eo-1A Lineage) 1
Outcome Breakdown
Died
69 (60.0%)
Euthanized
42 (36.5%)
Ongoing
4 (3.5%)
Gender Distribution
Female 93 (95.9%)
Unknown 4 (4.1%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2015 | 2 | |
| 2016 | 16 | |
| 2017 | 12 | |
| 2018 | 7 | |
| 2019 | 10 | |
| 2020 | 16 | |
| 2021 | 14 | |
| 2022 | 9 | |
| 2023 | 10 | |
| 2024 | 1 | |
Atlantic Salmon (Salmo salar) Pet Health Insights
Across the FDA Center for Veterinary Medicine adverse event database, Atlantic Salmon (Salmo salar) accounts for 97 submitted reports and currently ranks #232 by report volume within the fish population. Of those reports, 96 involved a death outcome — a 9900.0% case-fatality figure calculated directly from the underlying FDA records rather than from external mortality studies. The mean age at time of reporting is 0.7 years, with an average recorded body weight of 0.4 kg (0.9 lbs). These figures reflect the voluntary reporting pool only and should be read alongside breed popularity, veterinary access, and owner awareness — all of which shape how many events ever reach the FDA.
The most frequently reported clinical signs for Atlantic Salmon (Salmo salar) are Death (69 reports), IGA Animal mortality greater than expected (41 reports), Fish body deformity (31 reports), together capturing a substantial share of the top-reaction traffic seen in this breed's record. On the product side, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) appears in 88 reports and is the single most-referenced drug, followed by Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage (7) and Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A Locus In The Eo-1A Lineage) (1). Counts like these surface which therapeutic classes dominate the reporting stream — useful context when comparing reactions across breeds of the same fish species.
Outcome coding on the 115 reports with a recorded status is dominated by Died (60.0% of coded outcomes). Annual submission volume ranges from 2,015 to 2,024 reports across the 10 years on file, indicating the reporting trend is shaped as much by awareness cycles as by underlying clinical events. Because FDA adverse event reports describe correlation rather than causation, these numbers are most useful as a signal of where to ask further questions with a veterinarian — not as a standalone risk score for any individual fish.
Understanding Atlantic Salmon (Salmo salar) Adverse Event Data
Atlantic Salmon (Salmo salar) has 97 adverse event reports on file. Lower report volumes may reflect a less common breed, lower reporting rates, or genuinely fewer adverse events.
The 9900.0% death rate is above average, though this statistic should be interpreted cautiously. Death reports may be overrepresented because serious outcomes are more likely to be reported than mild reactions.
The most frequently referenced drug in adverse reports is Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage), appearing in 88 reports. This may indicate widespread use of the medication rather than a specific safety concern for Atlantic Salmon (Salmo salar).
Other Fish Breeds
Frequently Asked Questions
How many FDA adverse event reports involve Atlantic Salmon (Salmo salar)? ▼
There are 97 adverse event reports involving Atlantic Salmon (Salmo salar) in the FDA database, with 96 reports involving death (9900.0% death rate). Atlantic Salmon (Salmo salar) ranks #232 by report volume.
What are the most common adverse reactions reported for Atlantic Salmon (Salmo salar)? ▼
The most commonly reported adverse reactions for Atlantic Salmon (Salmo salar) are Death (69 reports), IGA Animal mortality greater than expected (41 reports), Fish body deformity (31 reports), Moribund (24 reports), IGA Animal morbidity greater than expected (17 reports).
What drugs are most frequently associated with Atlantic Salmon (Salmo salar) adverse events? ▼
The drugs most frequently referenced in Atlantic Salmon (Salmo salar) adverse event reports are Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) (88 reports), Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage (7 reports), Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A Locus In The Eo-1A Lineage) (1 reports), Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The Alocus In The Eo-1A Lineage) (1 reports).
What is the average age of Atlantic Salmon (Salmo salar) in adverse event reports? ▼
The average age of Atlantic Salmon (Salmo salar) at the time of adverse event reports is 0.7 years, with an average weight of 0.4 kg (0.9 lbs).
Does a high number of adverse event reports mean Atlantic Salmon (Salmo salar) is unhealthy? ▼
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this Atlantic Salmon (Salmo salar) safety data come from? ▼
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.
Guides & Resources
Understanding Adverse Events
What FDA reports are and how they are collected
Breed-Specific Risks
Why some breeds appear in more adverse event reports
Pet Medication Safety
Evaluating medication risks using FDA data
Most Reported Medications
Drugs that appear most in adverse event reports
How FDA CVM Tracks Events
The reporting process and database limitations
Related Data Sources
Data Sources & Methodology
Adverse event data sourced from the FDA Center for Veterinary Medicine via the openFDA Animal & Veterinary Adverse Events API. Reports are voluntarily submitted by pet owners, veterinarians, and product manufacturers.
Atlantic Salmon (Salmo salar) ranks #232 by total report volume. Death rate (9900.0%) reflects the proportion of reports involving death and should not be interpreted as a breed-specific mortality rate. Reporting biases, breed popularity, and veterinary access all influence report counts.
Read our methodology — how this data is sourced, computed, and verified.
Related
Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial